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Introduction 
Community-acquired methicillin-
resistant Staphylococcus aureus (CA-
MRSA) infections remain a growing 
problem despite the increasing 
armamentarium of anti-MRSA antibiotics. 
The majority of reported CA-MRSA 
infections are skin and soft tissue infections.  
Recently, more invasive and life-threatening 
infections have been recognized.1  
Ophthalmic infections have been reported 
less frequently and CA-MRSA endogenous 
endophthalmitis has not been well 
described.2 The clinical presentations, 
treatment, and outcome of two cases of 
suspected invasive CA-MRSA endogenous 
endophthalmitis are discussed in this report. 
 
Case Reports 
Case 1.  A 26-year-old man presented to 
a community hospital with a right arm 
subcutaneous abscess.  Incision and drainage 
was performed.  The wound culture grew 
MRSA sensitive to all antibiotics tested 
except oxacillin and penicillin.  He was 
treated with trimethoprim-sulfamethoxazole.  
Three days later, he developed lumbago.  
After two weeks of symptomatic treatment, 
Magnetic Resonance Imaging (MRI) 
appeared to demonstrate L5-S1 disk 
herniation.  Epidural corticosteroid injection 
was administered.  Five days later, he 
developed    syncope   and   supraventricular  
 
tachycardia.  He was transferred to our 
facility for evaluation.   
Laboratory results revealed leukocytosis 
of 17.1 x109/L, 32% bands, and erythrocyte 
sedimentation rate was 53 mm/hr.  He was 
started on vancomycin 15 mg/kg IV every 
12 hours.  Blood cultures grew MRSA, 
sensitive to fluoroquinolones and resistant to 
oxacillin and erythromycin (VITEK 
Automated Microbiology System).  Repeat 
MRI of the spine demonstrated discitis at the 
L5-S1 disk space with associated epidural 
abscess and vertebral osteomyelitis. 
Over the next three days, he developed 
hypoxic respiratory failure.  Repeat imaging 
revealed paravertebral abscesses, thrombosis 
of the adjacent inferior vena cava, and 
bilateral septic pulmonary emboli.  He 
underwent surgical drainage of the 
paravertebral process.   
On post-operative day four, examination 
revealed bilaterally injected conjunctiva.  
Ophthalmologic evaluation revealed 
bilateral endophthalmitis with vitreal 
abscesses.  A vitreous sample taken from the 
left eye revealed no growth (on antibiotic 
therapy).  Due to high suspicion for MRSA 
endophthalmitis, he received intravitreous 
clindamycin and vancomycin at doses of one 
milligram (mg) each of a 0.1 mL solution, 
followed by a change in systemic IV 
antibiotics to linezolid, 600 mg IV every 12 
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hours, and moxifloxacin, 400 mg IV every 
24 hours.  After several days, he clinically 
stabilized. After multiple interventions for 
retinal detachments over a period of months, 
his visual acuity improved to 20/20 in the 
right eye and 20/100 in the left.   
Case 2.  A 53-year-old female presented 
to an outside facility with shoulder pain.  
Joint aspiration was performed and cultures 
grew MRSA, resistant to penicillin, 
erythromycin, levofloxacin, and oxacillin 
without inducible clindamycin resistance.  
Blood cultures grew MRSA and intravenous 
antibiotics were initiated.  She also had 
tricuspid valve endocarditis and septic 
emboli to bilateral lungs with positive 
MRSA sputum cultures.  She developed 
decreased visual acuity and conjunctival 
injection.  Ophthalmologic involvement was 
suspected.  She was transferred to our 
facility for treatment. 
On arrival, she was tachycardic, 
tachypneic, and mildly hypoxic.  She had 
conjunctival erythema and edema of the 
right eye. Visual acuity was 20/50 and she 
was diagnosed with endophthalmitis per 
ophthalmologic examination.  Laboratory 
studies revealed leukocytosis of 35.2 
x109/L.  Chest radiograph demonstrated 
extensive bilateral multilobar infiltrates.  
MRI of the right shoulder confirmed 
osteomyelitis of the acromion and proximal 
humerus. 
During the hospitalization, she had 
repeat (negative) cultures of blood, 
acromioclavicular joint, and vitreous fluid 
from right eye (on antibiotic therapy).  She 
was treated with intravenous vancomycin 15 
mg/kg IV every 12 hours and gentamicin 80 
mg IV every 8 hours, then with rifampin 600 
mg IV twice daily.  She also received 
intravitreal vancomycin 1 mg of 0.1 mL 
solution to the right eye.  She developed a 
diffuse maculopapular rash on vancomycin 
and rifampin and daptomycin 6 mg/kg IV 
every 24 hours was substituted.  Sepsis 
improved and she was discharged to 
complete six weeks of daptomycin therapy.  
Visual acuity improved to 20/20 at the time 
of discharge. Work-up for an underlying 
immunodeficiency was negative in both 
cases. 
 
Discussion 
Staphylococcus aureus causes a wide 
array of human infection from limited skin 
involvement to profound septic shock.3 
While invasive S. aureus infection was once 
limited to hospital-acquired strains, CA-
MRSA has been emerging as a significant 
pathogen.1  There are increasing reports of 
invasive CA-MRSA blood stream infections 
and death.   
A clear delineation between community 
and health care-associated infections (HA-
MRSA) is important to understanding the 
spectrum of CA-MRSA infections.  This 
delineation is made possible by acceptance 
of more specific definitions and molecular 
testing.  New definitions propose HA-
MRSA should include patients with positive 
MRSA blood cultures greater than 48 hours 
into hospitalization, and those with home 
intravenous therapy, chemotherapy, home 
specialized nursing care, and hospital or 
hemodialysis clinic attendance within 30 
days before S. aureus bacteremia as well as 
those hospitalized in an acute care setting 
for two or more days in the preceding 90 
days or residence in a long-term care 
facility.4,5  Genetic testing also has helped to 
identify specific virulent factors associated 
with CA-MRSA which may explain its 
recently increased propensity to cause 
invasive infection. 
 Exogenous endophthalmitis, including 
S. aureus endophthalmitis, has been 
described extensively in post-operative 
ophthalmologic surgery.2,6,7  Endogenous 
endophthalmitis is much rarer, however, 
comprising only 5-10% of cases.8  S. aureus 
represents a minority of these cases and, 
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until recently, differentiation between HA-
MRSA and CA-MRSA was not made.   
In a review of MRSA infections of the 
eye in an urban healthcare system, 3640 
patients had a positive culture of MRSA and 
70% were suspected CA-MRSA.2  Of these, 
only four (8%) had endogenous 
endophthalmitis.  Two of these patients 
would not have had CA-MRSA based on 
Friedman’s definition.5  A 2005 review of 
necrotizing fasciitis cases in a large US 
medical center identified one patient who 
had co-existing endopthalmitis related to 
MRSA bacteremia.9 A 2006 review 
examined cases of MRSA culture positive 
patients at a US university and county 
hospital and found nine patients with the 
USA300 clone; three had endogenous 
endopthalmitis.10  A retrospective study of 
treatment of endophthalmitis identified 14 
cases of endogenous endophthalmitis over a 
four-year span.11  Only one patient had S. 
aureus, however, the strain was not 
identified as MRSA.  Another 7-year review 
of cases of endogenous endophthalmitis 
from a US university medical facility found 
21 cases; five were S. aureus and two were 
MRSA.  The strains were not identified 
further and based on information provided, 
only one remained as possible CA-MRSA.8  
While S. aureus represents a small 
percentage of reported pathogens in cases of 
endogenous endophthalmitis, additional 
reports of MRSA and CA-MRSA infections 
are being identified and more may be 
missed.  The true prevalence of MRSA 
endophthalmitis is unclear as availability of, 
and indications for, full ophthalmologic 
evaluation in MRSA bacteremia are 
unknown.  It is unclear if specific toxic 
production or protein expression increases 
the likelihood of endophthalmitis.  
Colonization with MRSA also has not been 
found universally in subjects with 
endogenous endopthalmitis.12  The 
aforementioned cases demonstrated need for 
vigilance in identifying endophthalmitis in 
patients with invasive MRSA infection.  
Reported cases, including our own, showed 
complications may be severe.  Endogenous 
MRSA endophthalmitis can result in 
significant visual loss.  In one series of 32 
patients with MRSA endophthalmitis, only 
36% of those with MRSA infections 
achieved visual acuity greater than 20/400 at 
three-month follow-up.13 Retinal detachment 
is also common.14  Goals should include 
early ophthalmologic evaluation and 
directed antibiotic treatment. 
Standard therapy of MRSA 
endophthalmitis has not been defined.  
While the most clinical experience with 
MRSA endophthalmitis lies with intravitreal 
vancomycin, acceptable intravitreal 
concentrations have been demonstrated with 
systemic vancomycin, fluoroquinolones, 
daptomycin, and linezolid making these 
potential treatment options.15,16  It is unclear 
if intravitreal antibiotics of these classes 
provide additional benefit to systemic 
therapy.  Appropriate number and interval 
between intravitreal injections is undefined.  
Retinal toxicity also may limit antibiotic 
usage. Further studies are required.  
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    Table 1.  Reported cases of CA-MRSA endogenous endophthalmitis. 
*Genetic testing performed.  **No genetic testing available, however, absence of HA-MRSA risk factors, community-
acquired infection known. ***Not enough provided information to exclude possibility of CA-MRSA.   
LP = light perception, HM = hand motion, CF= count fingers.
 Case Age/ 
Sex 
Proven 
CA-
MRSA* 
Suspected 
CA-
MRSA** 
Possible 
CA-
MRSA*** 
IV Treatment Vitreal Treatment Visual Acuity 
 
Our series 1 26/M  x  Vancomycin Vancomycin/Clindamycin 20/100 
2 53/F  x  Vancomycin, then 
Daptomycin and 
Rifampin 
Vancomycin 20/20 
Blomquist2 1 40/M  x  Not Reported Vancomycin/Ceftazidime Not Reported 
2 43/M  x  Vancomycin 
/Gentamicin 
Enucleation Not Reported 
Miller et al.9 1 45/M x Not Reported Not Reported Not Reported 
Ruter et al.10 1 39/M x   Vancomycin, 
Rifampin, 
Gentamicin 
Vancomycin 20/40 
2 43/M x Vancomycin Vancomycin 20/30 
3 39/M x   Vancomycin Vancomycin 20/30 
4 61/M x   Vancomycin Vancomycin, then 
Enucleation 
No LP 
Schiedler et al.8 1 75/F   x Vancomycin Vancomycin/Ceftazidime 20/25 
Ho et al.14 1 66/M   x Vancomycin Vancomycin/Ceftazidime 20/150 
2 38/F   x Vancomycin Vitrectomy HM 2 Feet 
3 74/M x Vancomycin None CF 2 Feet 
4 77/M   x Vancomycin Vancomycin/Ceftazidime 20/100 
5 49/F   x Vancomycin Vitrectomy Enucleation 
6 18/M  x  Vancomycin Vancomycin/Ceftazidime Left - HM 2 
Feet; Right - LP 
7 85/M   x Vancomycin Vancomycin/Ceftazidime 20/40 
Leibovitch et al.17 1 37/F   x Not Reported Not Reported No LP 
Ness et al.12 1 F   x Not Reported Not Reported Not Reported 
 2 M   x Not Reported Not Reported Not Reported 
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